We are testing a new treatment called BT200 for people with Type 2B von Willebrand disease. The goal is to see if it improves blood clotting and is safe for use.
Health conditions and diseases that the clinical trial is designed to study and treat.
Von Willebrand's Disease Type 2B is a genetic bleeding disorder that affects the blood's ability to clot, leading to excessive bleeding. It is characterized by a defect in the von Willebrand factor, which helps platelets stick to blood vessel walls.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.